NasdaqGS:INSMBiotechs
A Look At Insmed (INSM) Valuation After Robust Q1 2026 Results And Reiterated Guidance
Insmed (INSM) has drawn fresh investor attention after reporting first quarter 2026 results that combined significant revenue contributions from BRINSUPRI and ARIKAYCE with a smaller net loss and reiterated full year guidance.
See our latest analysis for Insmed.
Despite the solid Q1 update and reiterated guidance, the stock has recently pulled back, with a 30 day share price return of down 21.93% and a year to date share price return of down 33.38%. At the same time, the 1 year total...